Chr Hansen A/S : Q1 Investor presentation 2021/22

Chr. Hansen Q1 2021/22

Investor presentation January 13, 2022

Safe harbor statement

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Forward-looking statements are other than statements of historical facts. The words "believe," "expect," "anticipate," "intend," "estimate," "outlook," "will," "may," "continue," "should" and similar expressions identify forward-looking statements.

Forward-looking statements include statements regarding objectives, goals, strategies, outlook and growth prospects; future plans, events or performance and potential for future growth; liquidity, capital resources and capital expenditures; economic outlook and industry trends; developments of the Company's markets; the impact of regulatory initiatives; and the strength of competitors. The forward-looking statements in this presentation are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management's examination of historical operating trends, data contained in records and other data available from third parties.

Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and may be beyond our control. Such risks, uncertainties, contingencies and other important factors could cause the actual results of the Company or the industry to differ materially from those results expressed or implied in this presentation by such forward-looking statements.

The information, opinions and forward-looking statements contained in this presentation speak only as at the date of this presentation and are subject to change without notice. The Company and its respective agents, employees or advisors do not intend to, and expressly disclaim any duty, undertaking or obligation to, make or disseminate any supplement, amendment, update or revision to any of the information, opinions or forward- looking statements contained in this presentation to reflect any change in events, conditions or circumstances beyond what is required by applicable law or applicable stock exchange rules and regulations.

By viewing this presentation, you acknowledge and agree to be bound by the foregoing limitations and restrictions.

2

A solid start to the year

Financial highlights Q1 2021/22

ORGANIC GROWTH	EBIT MARGIN	FREE CASH FLOW
	before special items	before acquisitions and special items
9%	24.4%	EUR 55m

3

Good progress on strategic initiatives across core and lighthouses

Strategic and operational highlights Q1 2021/22

2025 STRATEGY

REINVEST1

in core businesses to defend and further strengthen market position

~90% of revenue Q1 2021/22

LEVERAGE1

technology platform to expand into new growth areas (lighthouses)

~10% of revenue Q1 2021/22

FC&E with strong project		Stronger-than-expected start
execution in EMEA and good		for Human Health driven by
momentum in cheese		market rebound, new wins and
in North America		strong supply performance

HMO growth	Plant Health entered
supported by customer	partnership with UPL to bring
launches of 5HMO mix	microbial crop protection to
in North America	market

ORGANIC GROWTH

Q1 2021/22
	35%
		9%
7%
REINVEST 1	LEVERAGE1	Group

1 REINVEST includes FC&E ex. Bioprotection and Fermented Plant Bases, Human Health and Animal Health. LEVERAGE includes Bioprotection, Fermented Plant Bases, HMO and Plant Health.

4

Bacthera reached an important milestone

with Seres Therapeutics commercial manufacturing agreement

COMMERCIAL

MANUFACTURING

AGREEMENT

LIVE BIOTHERAPEUTIC MARKET

Clinical supply market	Commercial supply
slower due to delays	market materializing
in clinical trials	faster than expected	SER-109	New site in Visp
		has the potential to become the	for commercial manufacturing to
		first-ever live biotherapeutic product	be established until 2024

5